Key result
Real-time continuous glucose monitoring (CGM) has a potential role in preventing hypoglycemia and overcoming barriers to the implementation of intensive diabetes therapy.
Why the study?
Does real-time continuous glucose monitoring prevent hypoglycemia in patients on intensive diabetes therapy?
Does real-time continuous glucose monitoring prevent hypoglycemia in patients on intensive diabetes therapy?
Real-time continuous glucose monitoring may play a role in preventing hypoglycemia and overcoming barriers to intensive diabetes therapy.
May support CGM consideration to reduce hypoglycemia barriers in intensive therapy; leaves open confirmation in prospective trials.
Intensive diabetes therapy is complicated by an increased rate of hypoglycemia and the development of hypoglycemia unawareness. This presentation focuses on the potential role of real-time continuous glucose monitoring (CGM) in preventing hypoglycemia, and in overcoming this barrier to the implementation of intensive therapy. Issues to be discussed include the differences between capillary blood and interstitial glucose levels, the impact of lag times on sensor calibration and accuracy, and the importance of patient education in minimizing the risk for hypoglycemia from uncontrolled postprandial bolusing.
No takes yet. Share an insight, caveat, or question.
Howard Wolpert (2007) conducted a review in Diabetes with hypoglycemia. Real-time continuous glucose monitoring (CGM) was evaluated. Real-time continuous glucose monitoring (CGM) has a potential role in preventing hypoglycemia and overcoming barriers to the implementation of intensive diabetes therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: